Reference
  1. Alashi A, Smedira NG, Popovic ZB, et al. Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2021 Feb 2;10(3):e018527. doi: 10.1161/JAHA.120.018527. Epub 2021 Jan 28. PMID: 33506683; PMCID: PMC7955450.
  2. Barry J. Maron, M.D.,Clinical Course and Management of Hypertrophic Cardiomyopathy, N Engl J Med 2018;379:655-68. DOI: 10.1056/NEJMra1710575.
  3. Cirino AL, Ho C., Hypertrophic Cardiomyopathy Overview,GeneReviews® [Internet].Seattle (WA): University of Washington, Seattle; 1993-2022.
  4. Funder JW, Carey RM , Fardella C , et al.Case detection , diagnosis, and treatment of patients with primary aldosteronism :an endocrine society clinical practice guideline[ J] .J Clin Endocrin ol Metab , 2008 , 93:3266-3281
  5. Fernandes-RosaFL, DaniilG, OrozcoIJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 2018;50:355-361. [PubMed: 29403012]
  6. ChoiM, SchollUI, YueP, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772. [PubMed: 21311022]
  7. SchollUI, GohG, StoltingG, et al.Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013;45:1050-1054. [PubMed: 23913001]
  8. Morill as P , C astillo J, Quiles J, et al.Prevalence of primary aldosteronism in hypertensive patients and its eff ect on the heart[ J] . Rev Esp Cardiol , 2008, 61:418-421
  9. Byrd JB, Turcu AF, Auchus RJ. Primary Aldosteronism: Practical Approach to Diagnosis and Management. Circulation. 2018 Aug 21;138(8):823-835. doi: 10.1161/CIRCULATIONAHA.118.033597. PMID: 30359120; PMCID: PMC6205759.
10.Perry M. Elliott,Aris Anastasakis, Michael A. Borger,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.European Heart Journal (2014) 35, 2733–2779 doi:10.1093/eurheartj/ehu284